OMN51
Multidrug‑resistant Gram‑negative bacterial infections (e.g., Pseudomonas aeruginosa)
PreclinicalActive
Key Facts
Indication
Multidrug‑resistant Gram‑negative bacterial infections (e.g., Pseudomonas aeruginosa)
Phase
Preclinical
Status
Active
Company
About Omnix Medical
Omnix Medical engineers stable, selective antimicrobial peptides to address the global crisis of antibiotic‑resistant infections.
View full company profile